By the num­bers for 2018: The top 100 ven­ture play­ers in biotech — and who's been pay­ing the piper in can­cer R&D?

The ex­plo­sion of on­col­o­gy R&D over the past few years has had a dra­mat­ic im­pact on a va­ri­ety of fronts, all clear­ly il­lus­trat­ed in these line­ups of the top 100 ven­ture in­vestors in biotech from Chris Doko­ma­ji­lar at Deal­For­ma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.